miR-34C Disrupts the Stemness of Purified CD133+ Prostatic Cancer Stem Cells

被引:8
|
作者
Chen, Yuan
Rao, Qun
Zhang, Huiping
Xu, Hua
Zhang, Cuntai
Zhuang, Qianyuan
Ye, Zhangqun [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Urol, Wuhan 430030, Peoples R China
关键词
ANDROGEN RECEPTOR; THERAPY; IDENTIFICATION; EXPRESSION; RESISTANCE; MICRORNA; PROMOTES;
D O I
10.1016/j.urology.2016.07.021
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To find the potential micro-RNA (miRNA) that could determine the fate of prostate cancer stem cells. MATERIALS AND METHODS We compared miRNA expression between our purified CD133(+) prostatic cancer stem cells (PCSCs) and CD133-cells. Sphere formation assay and matrigel-based cell invasion assay were applied to determine the stemness of CD133(+) PCSCs after our manipulation of miRNA using miRNA mimic or miRNA inhibitor. RESULTS In this study, we identified that miR-34C was under-expressed in the purified CD133(+) PCSCs and enforced introduction of miR-34C attenuated the stemness of CD133(+) PCSCs. Clinically, we also observed a negative correlation between miR-34C and CD133. CONCLUSION Our data strongly suggest that miR-34C may play essential role in conferring castration resistance by equilibrating PSCS population. (C) 2016 Elsevier Inc.
引用
收藏
页码:177.e1 / 177.e9
页数:9
相关论文
共 50 条
  • [31] Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer
    Wang, Qi
    Chen, Zhi-Guo
    Du, Chang-Zheng
    Wang, Hong-Wei
    Yan, Li
    Gu, Jin
    HISTOPATHOLOGY, 2009, 55 (03) : 284 - 293
  • [32] CD133+ Cells Are Resistant to Anoikis in Pancreatic Cancer
    Moriyama, T.
    Ohuchida, K.
    Lin, C.
    Ikenaga, N.
    Sakai, H.
    Mizumoto, K.
    Tanaka, M.
    PANCREAS, 2009, 38 (08) : 1029 - 1029
  • [33] miR-199a and miR-34c enhance the migration of prostate cancer stem cells but inhibit migration of PC3 prostate cancer cells
    Sun, Xinghui
    Wu, Weizhen
    Zheng, Kai
    Chen, Binghua
    Tan, Jianming
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (04): : 6791 - 6800
  • [34] Cisplatin selects for CD133+ cells in lung cancer cells
    Jiaheng Li
    Mei Jiang
    Xiaoting Zhao
    Ziyu Wang
    Meng Gu
    Weiying Li
    Oncology and Translational Medicine, 2020, 6 (01) : 16 - 20
  • [35] Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells
    T Baba
    P A Convery
    N Matsumura
    R S Whitaker
    E Kondoh
    T Perry
    Z Huang
    R C Bentley
    S Mori
    S Fujii
    J R Marks
    A Berchuck
    S K Murphy
    Oncogene, 2009, 28 : 209 - 218
  • [36] CD133+ cancer stem cells promoted by VEGF accelerate the recurrence of hepatocellular carcinoma
    Kai Liu
    Meijun Hao
    Yabo Ouyang
    Jiasheng Zheng
    Dexi Chen
    Scientific Reports, 7
  • [37] CD133+ Stem Cells in the Treatment of Patients With Refractory Angina
    Willerson, James T.
    CIRCULATION RESEARCH, 2017, 120 (04) : 602 - 603
  • [38] Stem cells in T-ALL have a primitive CD133+/CD34+/CD7-phenotype.
    Cox, CV
    Evely, RS
    Goulden, NJ
    Blair, A
    BLOOD, 2004, 104 (11) : 522A - 522A
  • [39] Down-expression of miR-154 suppresses tumourigenesis in CD133+ glioblastoma stem cells
    Yang, Liang
    Yan, Zhongjie
    Wang, Yuanyu
    Ma, Wandong
    Li, Chen
    CELL BIOCHEMISTRY AND FUNCTION, 2016, 34 (06) : 404 - 413
  • [40] CD133+ cancer stem cells promoted by VEGF accelerate the recurrence of hepatocellular carcinoma
    Chen, Dexi
    Liu, Kai
    Hao, Meijun
    Ouyang, Yabo
    Zheng, Jiasheng
    Challagundla, Kishore Babu
    CANCER RESEARCH, 2017, 77